Navigation Links
Salix Pharmaceuticals Previews Digestive Disease Week 2007

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of 18 investigator-initiated trials related to the Company's products will be presented at Digestive Disease Week(R) 2007, which will be held May 19-24, 2007. Digestive Disease Week is considered the largest and most prestigious meeting in the world for the GI professional. Every year it attracts more than 16,000 physicians, researchers and academics from around the world who desire to stay up-to-date in their respective fields. The meeting is the year's best opportunity to learn about the latest advances in gastroenterology, hepatology, endoscopy and gastrointestinal surgery; prevention, diagnosis and treatment of digestive disorders; and cutting-edge technological advances.

POSTER PRESENTATIONS: -0-

TOPIC                                        LEAD AUTHOR        DATE

---------------------------------------- -------------------- --------


XIFAXAN

An open label series of rifaximin for     A. Kornbluth, M.D.   May 20

 long term maintenance therapy for

 patients with refractory pouchitis


History of hypothyroidism is associated   E. Lauritano, M.D.   May 20

 to small intestinal bacterial

 overgrowth


High dosage rifaximin for the treatment  E. Scarpellini, M.D.  May 20

 of small intestinal overgrowth


High recurrence of small intestinal       E. Lauritano, M.D.   May 20

 bacterial overgrowth after antibiotic


Rifaximin versus systemic antibiotics     M. Gabrelli, M.D.    May 20

 for the treatment of small bowel

 bacterial overgrowth


Small intestinal bacterial overgrowth in   A. Parodi, M.D.     May 20

 acromegalic patients


May breath test be useful in diagnosis     A. Parodi, M.D.     May 20

 of IBS patients? an Italian Study


The oral nonsystemic antibiotic            H. DuPont, M.D.     May 20

 rifaximin prevents symptom recurrence

 in patients with recurrent C.

 difficile-associated diarrhea


Characterization o
'"/>




Page: 1 2 3 4 5 

Related medicine technology :

1. Salix Pharmaceuticals Announces Positive Top Line Results of
Balsalazide Tablets Registration Study
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Salix Pharmaceuticals Previews Digestive Disease Week
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... and SYDNEY , May 16, ... - ASX: HIN), a leading innovator of less invasive, miniaturized ... heart failure, today announced that CEO Doug Godshall ... Global Healthcare Conference at 11:00 a.m. EDT on Monday, May ... at the Sheraton New York Hotel. A live ...
(Date:5/16/2013)... May 16, 2013 OrthoView PSL ... U.S. to access the widely-used OrthoView digital templating software ... Internet connection to get started. OrthoView, the ... over 10 years, is dedicated to enabling orthopaedic surgeons ... x-ray images, when printed film is unavailable. Over 5,000 ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2
... Study Confirms Role of AMBIEN CR in Effectively Managing Insomnia ... Improve Quantity and Quality of Work Performance, ... new study that showed patients with chronic,insomnia who were treated ... CIV experienced significant improvements in two,key parameters of work performance ...
... a division of Wyeth (NYSE: WYE ), ... (FDA) has accepted for filing the,Company,s supplemental New ... for the treatment of patients with,community-acquired pneumonia (CAP). ... application. The FDA may approve or disapprove the ...
Cached Medicine Technology:New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV 2New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV 3New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV 4FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 2FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 3FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 4FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 5FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 6
(Date:5/19/2013)... Farming methods have changed many times since man ... ago. Most recently, the Green Revolution has transformed farming ... seeds and by applying chemical fertilizers and pesticides. But ... due to the adverse environmental and health effects of ... interest in organic, sustainable farming practices and techniques. Enter ...
(Date:5/19/2013)... Vegas Hotel Escapes, the premier ... the launch it's all new vacation packages for the ... 5/19/2013. Consumers traveling to Las Vegas will be pleased ... VegasHotelEscapes.com's website. Travelers will be pleased to know that ... , Vegas Hotel Escapes specializes in helping consumers ...
(Date:5/19/2013)... May 19, 2013 Exciting new Skin ... is reintroducing a great practice known through the ages ... known as dry body brushing, has so many benefits ... of Sublime Beauty®. "We love that circulation and lymphatic ... largest organ, the skin, is supported through Skin Brushing." ...
(Date:5/19/2013)... Buenos Aires, Argentina: Yoga classes ( clases de ... Argentina by the Sivananda Yoga Vedanta Center. The ... (Barrio Norte). Classes are 90 minutes and are offered ... in a calm environment, allowing visitors to enjoy the ... food, among others. , The Yoga classes follow the ...
(Date:5/19/2013)... Minor fender benders and serious car accidents are ... the accident to respond appropriately to the situation. ... data from 2010, accidents, including car accidents, are the ... in 2005, automobile accident-related deaths cost over ... million drivers and passengers receive treatment in an emergency ...
Breaking Medicine News(10 mins):Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2
... HealthDay Reporter , MONDAY, Nov. 7 (HealthDay News) - More ... drugs, with 32 percent saying they drink, 19 percent saying they ... study shows. , , An even closer look at the data ... to use drugs or alcohol, with almost 48 percent admitting they ...
... by 2007 annual sales of the cards were at 85,000. America ... in the U.S. over the age of 80 is expected to ... how well they live. The new book, Aging Our Way ... of 30 eldersranging in age from 85 to 102living at home ...
... the Johns Hopkins Center for Injury Research and Policy ... a strategic, comprehensive and coordinated approach to fire prevention. ... the state,s fire service, highlights the diversity of prevention ... dedication, and a sense of community are keys to ...
... (November XX, 2011) The Lymphoma Division of the John ... participation from the Facebook groups "Hope for Lymphoma" and "Our ... on Saturday, November 12 from 8:30am 3:45pm. The ... Mantle Cell Lymphoma (MCL) patients and their caregivers coping with ...
... A grant in excess of $3.5 million has been awarded ... to facilitate the production of new and investigational drugs for ... Central Texas cancer research program receiving the award from the ... to fund innovation and commercialization of cancer research in the ...
... published online Nov. 6 in Nature Medicine , investigators ... the development of osteoarthritis is in great part driven by ... view attributing the condition to a lifetime of wear and ... William Robinson, MD, PhD, the study,s senior author, of the ...
Cached Medicine News:Health News:More Than a Third of Teens Turning to Alcohol, Drugs: Study 2Health News:More Than a Third of Teens Turning to Alcohol, Drugs: Study 3Health News:What can we learn from America's fastest growing and least understood age group? 2Health News:Delaware Fire Service offers important lessons for fire prevention programs nationwide 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 2Health News:John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium 3Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 2Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 3Health News:Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: